Kiniksa medical chief Paolini sells 96,000 shares

A Rule 10b5-1 plan executed on July 29, 2026 covered these reported transactions.

Available on EDGAR 11/03/2026 - 06:29 PM EST Accepted by SEC EDGAR 11/03/2026 - 06:28 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) Chief Medical Officer John F. Paolini exercised options for 96,000 Class A ordinary shares on October 30 and November 2, 2026, at exercise prices of $17.92 and $30.93 per share. He sold 96,000 shares across those dates at reported weighted-average sale prices including $92.02 and $97.77 per share. The transactions were effected under a Rule 10b5-1 plan executed July 29, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 96,000 shares ($6.63M approx. pre-tax spread)

Exercise and Sale 18 txns

Insider Paolini John F.

Role CHIEF MEDICAL OFFICER

Sold 96,000 shs ($8.94M)

Approx. gross sale proceeds $8.94M

Approx. exercise cost $2.31M

Approx. pre-tax spread $6.63M

Type	Security	Shares	Price	Value
Exercise	Share Option F1, F12	6,455	$0.00	$0.00
Exercise	Share Option F1, F12	11,958	$0.00	$0.00
Exercise	Class A Ordinary Share F1	6,455	$30.93	$200K
Exercise	Class A Ordinary Share F1	11,958	$17.92	$214K
Sale	Class A Ordinary Share F1, F9	899	$92.37	$83K
Sale	Class A Ordinary Share F1, F10	16,810	$93.42	$1.57M
Sale	Class A Ordinary Share F1, F11	704	$94.09	$66K
Exercise	Share Option F1, F12	38,545	$0.00	$0.00
Exercise	Share Option F1, F12	39,042	$0.00	$0.00
Exercise	Class A Ordinary Share F1	38,545	$30.93	$1.19M
Exercise	Class A Ordinary Share F1	39,042	$17.92	$700K
Sale	Class A Ordinary Share F1, F2	41,789	$92.02	$3.85M
Sale	Class A Ordinary Share F1, F3	16,056	$92.85	$1.49M
Sale	Class A Ordinary Share F1, F4	6,841	$93.91	$642K
Sale	Class A Ordinary Share F1, F5	4,821	$94.86	$457K
Sale	Class A Ordinary Share F1, F6	4,000	$95.97	$384K
Sale	Class A Ordinary Share F1, F7	1,925	$97.06	$187K
Sale	Class A Ordinary Share F1, F8	2,155	$97.77	$211K

Holdings After Transaction: Share Option — 0 contracts (Direct); Class A Ordinary Share — 69,922 shares (Direct)

Footnotes (12)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 29, 2026.
2. F2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.3575 and $92.355. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
3. F3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.36 and $93.35. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
4. F4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.42 and $94.385. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
5. F5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.42 and $95.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
6. F6. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.465. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
7. F7. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.565 and $97.415. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
8. F8. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.60 and $98.30. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
9. F9. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.00 and $92.805. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
10. F10. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.02 and $94.00. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
11. F11. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.025 and $94.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
12. F12. The option is fully vested and exercisable.

Key Figures

Shares acquired through option exercises: 96,000 Class A ordinary shares Shares sold: 96,000 Class A ordinary shares Exercise price: $17.92 per share +3 more

6 metrics

Shares acquired through option exercises 96,000 Class A ordinary shares October 30 and November 2, 2026

Shares sold 96,000 Class A ordinary shares October 30 and November 2, 2026

Exercise price $17.92 per share Option exercises on October 30 and November 2, 2026

Exercise price $30.93 per share Option exercises on October 30 and November 2, 2026

Weighted-average sale price $92.02 per share 41,789 shares sold on October 30, 2026

Weighted-average sale price $97.77 per share 2,155 shares sold on October 30, 2026

Key Terms

Rule 10b5-1 plan, weighted average sales price, fully vested and exercisable

3 terms

Rule 10b5-1 plan regulatory

"transaction was effected pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sales price financial

"reflects a weighted average sales price"

fully vested and exercisable financial

"The option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KNSA shares did John F. Paolini sell, and at what prices?

John F. Paolini sold 96,000 Class A ordinary shares across October 30 and November 2, 2026. Reported weighted-average sale prices included $92.02 and $97.77 per share; the transactions were effected under a Rule 10b5-1 plan executed July 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paolini John F.

(Last) (First) (Middle)

C/O KINIKSA PHARMACEUTICALS INT'L

105 PICCADILLY, SECOND FLOOR

(Street)

LONDON W1J 7NJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	10/30/2026		M(1)		38,545	A	$30.93	108,467	D
Class A Ordinary Share	10/30/2026		M(1)		39,042	A	$17.92	147,509	D
Class A Ordinary Share	10/30/2026		S(1)		41,789	D	$92.02(2)	105,720	D
Class A Ordinary Share	10/30/2026		S(1)		16,056	D	$92.85(3)	89,664	D
Class A Ordinary Share	10/30/2026		S(1)		6,841	D	$93.91(4)	82,823	D
Class A Ordinary Share	10/30/2026		S(1)		4,821	D	$94.86(5)	78,002	D
Class A Ordinary Share	10/30/2026		S(1)		4,000	D	$95.97(6)	74,002	D
Class A Ordinary Share	10/30/2026		S(1)		1,925	D	$97.06(7)	72,077	D
Class A Ordinary Share	10/30/2026		S(1)		2,155	D	$97.77(8)	69,922	D
Class A Ordinary Share	11/02/2026		M(1)		6,455	A	$30.93	76,377	D
Class A Ordinary Share	11/02/2026		M(1)		11,958	A	$17.92	88,335	D
Class A Ordinary Share	11/02/2026		S(1)		899	D	$92.37(9)	87,436	D
Class A Ordinary Share	11/02/2026		S(1)		16,810	D	$93.42(10)	70,626	D
Class A Ordinary Share	11/02/2026		S(1)		704	D	$94.09(11)	69,922	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$30.93	10/30/2026		M(1)			38,545	(12)	09/19/2028	Class A Ordinary Share	38,545	$0	6,455	D
Share Option	$17.92	10/30/2026		M(1)			39,042	(12)	03/03/2029	Class A Ordinary Share	39,042	$0	11,958	D
Share Option	$30.93	11/02/2026		M(1)			6,455	(12)	09/19/2028	Class A Ordinary Share	6,455	$0	0	D
Share Option	$17.92	11/02/2026		M(1)			11,958	(12)	03/03/2029	Class A Ordinary Share	11,958	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 29, 2026.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.3575 and $92.355. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.36 and $93.35. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.42 and $94.385. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

5. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.42 and $95.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

6. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.465. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

7. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.565 and $97.415. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

8. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.60 and $98.30. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

9. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.00 and $92.805. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

10. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.02 and $94.00. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

11. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.025 and $94.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

12. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	11/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)